Additionally, the ADAURA trial in EGFR-positive NSCLC and the ALINA trial in ALK-positive NSCLC have highlighted the survival benefits of targeted adjuvant therapy in eligible patients10,11. Here, EGFR is linked to non-small cell lung carcinoma.